Intelligent Bio Solutions Announced Growth Metrics
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is making strides in the medical technology sector, specifically through its innovative approach to rapid, non-invasive testing solutions. Recently, the company disclosed preliminary revenue results for its fiscal fourth quarter and highlighted key operational advancements. These developments indicate a promising trajectory for the company.
Steady Revenue Growth Expected
Management anticipated a revenue increase of approximately 16% compared to both the previous quarter and the same period last year. This growth underlines the rising demand for Intelligent Bio Solutions' higher-margin cartridge sales, reflecting a solid account expansion.
CEO Insights
Harry Simeonidis, President and CEO of Intelligent Bio Solutions, expressed confidence in the company's roadmap. He stated, "Fiscal 2025 was a year of strategic execution, and we expect continued revenue growth in the fourth quarter. Our strong performance has been complemented by significant advancements in our regulatory pathway as we pursue FDA 510(k) clearance, coupled with operational scaling worldwide."
Operational Highlights: Strengthening Global Presence
As part of its ongoing expansion strategy, Intelligent Bio Solutions has undertaken several operational enhancements:
- The company submitted its FDA 510(k) application for its opiate test system, incorporating updated scientific validation data.
- Improvements to the Intelligent Fingerprinting Drug Screening System were made to support wider global adoption.
- Localized websites and improved CRM workflows were launched to better engage partners and end-users across various regions, including Europe, the Middle East, and Latin America.
Future Outlook: Preparing for Market Entry
The preliminary, unaudited revenue figures for the fourth quarter are based on the information management has compiled to date and are subject to adjustments as the company completes its year-end financial processes. Comprehensive financial results are expected to be released in the imminent Annual Report on Form 10-K, which will be filed with the appropriate securities authorities shortly after the fourth quarter concludes.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. is a medical technology innovator providing groundbreaking solutions for drug screening through health-focused technologies. The Intelligent Fingerprinting Drug Screening System exemplifies the company's commitment to revolutionizing portable testing via fingerprint sweat analysis.
This hygienic and cost-effective testing method screens for recent drug use, offering results within minutes—making it an essential resource for employers in industries where safety is paramount. The company serves various customer segments, including construction, logistics, engineering, and drug treatment.
Company Contact
For additional inquiries, please reach out to Intelligent Bio Solutions Inc. at info@ibs.inc or connect with them on social media platforms such as LinkedIn and Twitter.
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
Phone: (212) 896-1254
Email: INBS@kcsa.com
Frequently Asked Questions
What growth metric did Intelligent Bio Solutions project for the fourth quarter?
They anticipate approximately 16% revenue growth sequentially and year-over-year.
What recent regulatory advancements has Intelligent Bio Solutions made?
The company submitted FDA 510(k) applications for its drug screening technology.
How does the Intelligent Fingerprinting Drug Screening System work?
This system analyzes fingerprint sweat for recent drug use, offering quick, non-invasive results.
Which sectors does Intelligent Bio Solutions serve?
The company caters to industries like construction, transport, and manufacturing, focusing on safety-critical environments.
How can I contact Intelligent Bio Solutions for more information?
You can reach them at info@ibs.inc or through their social media channels.
